Название продукции:8-Chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine

IUPAC Name:8-chloro-2-(methylsulfanyl)pyrimido[5,4-d][1,3]diazine

CAS:176637-10-8
Молекулярная формула:C7H5ClN4S
Чистота:95%+
Номер в каталоге:CM167362
Молекулярная масса:212.66

Упаковочная единица Доступно для заказа Цена ($) Количество
CM167362-250mg in stock Əǎǟ
CM167362-500mg in stock ţŽţ
CM167362-1g in stock ŽijŽ
CM167362-5g 1-2 Weeks ƏĜǟǟ
CM167362-10g 1-2 Weeks ŁţǟĜ

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:176637-10-8
Молекулярная формула:C7H5ClN4S
Точка плавления:-
Smiles-код:CSC1=NC=C(N=CN=C2Cl)C2=N1
Плотность:
Номер в каталоге:CM167362
Молекулярная масса:212.66
Точка кипения:
Номер Mdl:MFCD00227587
Хранение:Store at 2-8°C.

Column Infos

Zongertinib
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients.
Zongertinib (also known as BI 1810631) is an investigational oral HER2-specific tyrosine kinase inhibitor (TKI) that is being developed as a potential treatment for HER2 mutated non-small cell lung cancer (NSCLC). Zongertinib was granted FDA Fast Track Designation in 2023, then in 2024 it was granted Breakthrough Therapy Designation by the U.S. FDA and China CDE for the treatment of adult patients with advanced NSCLC whose tumors have activating HER2 mutations, and who have received a prior systemic therapy.

Related Products